公开(公告)号：US20200016211A1

公开(公告)日：2020-01-16

申请号：US16490790

申请日：2018-02-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yui Ueno ,  Hidenori Nonaka

IPC: A61K35/28 ,  A61K38/17

Abstract: The purpose of the present invention is to provide a mesenchymal stem cell that is highly safe when used as a medicine. The present invention is a mesenchymal stem cell characterized in that the Tissue Factor (TF) is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA11, ITGA1, ITGB5, ITGBL1, ITGB1 and ITGAV is expressed at low levels. Furthermore, the present invention includes a mesenchymal stem cell characterized in that at least one integrin gene selected from the group consisting of ITGA4, ITGA9, ITGA7, and ITGA10 is expressed at high levels. It is preferable that the mesenchymal stem cell is allogeneic and is derived from a fatty tissue. The present invention also includes a pharmaceutical composition containing the mesenchymal stem cell.

公开(公告)号：US20190125877A1

公开(公告)日：2019-05-02

申请号：US16094919

申请日：2017-04-21

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Yasuko Matsumura

IPC: A61K47/26 ,  A61K9/00 ,  A61K31/045 ,  A61K31/14 ,  A61K31/355 ,  A61K47/44 ,  A61K47/10 ,  C08J5/00

Abstract: The first aspect of the present invention relates to an ophthalmic composition comprising (A) one or more kinds selected from the group consisting of terpenoid, a tocopherol, and a benzyl ammonium compound and a salt thereof, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.The second aspect of the present invention relates to an ophthalmic composition comprising (A2) a surface active component and (B2) a buffer, wherein the ophthalmic composition is contained in a container in which a portion or the whole of a part coming into contact with the ophthalmic composition is formed from a resin containing a cyclic olefin.

公开(公告)号：US20190119621A1

公开(公告)日：2019-04-25

申请号：US15766194

申请日：2016-10-19

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tetsuo Koike ,  Masahiro Takimoto ,  Yoshiki Yagi

IPC: C12M1/00 ,  C12M1/12 ,  C12M3/00 ,  C12M1/36 ,  G06T7/00

Abstract: Provided is a cell treatment apparatus including a treatment chamber that is configured to secure a space for arranging therein a plurality of containers for use in treatment of cells in an inner space maintained in aseptic conditions, a gripping mechanism that is arranged in the treatment chamber and is configured to grip the plurality of containers arranged in the space, wherein the plurality of containers are capable of being arranged in the space so as to have their positions matched with predetermined positions of the plurality of containers so that the gripping mechanism can grip a container to be selected based on a command from among the plurality of containers.

公开(公告)号：USD841153S1

公开(公告)日：2019-02-19

申请号：US29581607

申请日：2016-10-20

Applicant: Rohto Pharmaceutical Co., Ltd.

Designer： Shigehiko Kokubo

公开(公告)号：US20180289812A1

公开(公告)日：2018-10-11

申请号：US15766514

申请日：2016-11-22

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Aki Kiyomiya ,  Takahiro Kurose ,  Atsuko Nakata ,  Xiang Zheng

IPC: A61K47/32 ,  A61K47/34 ,  A61K47/44 ,  G02C7/04

Abstract: The inventive ophthalmic composition comprises: (A) polyvinyl pyrrolidone K90; and (B) at least one selected from the group consisting of an oil component, a grease component and polyethylene glycol. The ophthalmic composition alleviates a sticky sensation to ensure an excellent use sensation.

公开(公告)号：US20180282681A1

公开(公告)日：2018-10-04

申请号：US15764779

申请日：2016-10-19

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tetsuo Koike ,  Masahiro Takimoto ,  Yoshiki Yagi

IPC: C12M1/00 ,  C12M3/00 ,  B25J9/16 ,  B25J9/00 ,  B25J13/08

Abstract: A cell treatment apparatus includes: a treatment chamber that is configured to treat cells; trays that are each configured to house containers for use in the treatment of cells in the treatment chamber, while positioning them; a gripping mechanism that is configured to grip and move at least one kind of the containers housed in each of the trays within the treatment chamber; and a container correct/incorrect determining apparatus that includes a storage device that is configured to prestore given postures of the containers relative to the each corresponding tray, an imaging device that is configured to image the containers arranged in the tray, and a determining device that is configured to determine whether the postures of the containers relative to the tray that are stored in the storage device are matched with postures of the containers relative to the tray that have been imaged by the imaging device.

公开(公告)号：US20180066218A1

公开(公告)日：2018-03-08

申请号：US15553847

申请日：2016-03-03

Applicant: Rohto Pharmaceutical Co., Ltd.

Inventor： Tetsuo Koike ,  Masahiro Takimoto ,  Yoshiki Yagi

IPC: C12M1/32 ,  C12M3/00 ,  B25J15/08 ,  B25J18/00

CPC classification number: C12M1/32 ,  B25J15/08 ,  B25J18/007 ,  C12M3/00 ,  C12M23/38 ,  C12M23/44 ,  C12M23/50 ,  C12M33/10 ,  C12M37/00 ,  C12M41/14 ,  C12M41/36 ,  C12M41/48

Abstract: Provided is an apparatus to produce cultured cell products including: an incubator configured to house cell culture vessels; an isolator configured to process the cell culture vessels conveyed from the incubator; and a pass box capable of carrying, into the isolator, articles and reagents, wherein the isolator includes: an observation section including first robot arms configured to move the cell culture vessels to an observation position so as to check the degree of growth of the cells in the cell culture vessels taken out of the incubator; a processing section including second robot arms configured to perform various processes to transfer the cells in the cell culture vessels that have a specified number of cells into product containers; and an outlet configured to allow a large number of product containers into which the cells have been transferred to be taken out therethrough.

公开(公告)号：US09724312B2

公开(公告)日：2017-08-08

申请号：US14154688

申请日：2014-01-14

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Takahiro Kurose ,  Takayuki Miyano ,  Mariyo Kato ,  Yoshihiro Takai

IPC: A61K31/121 ,  A61K47/02 ,  A61K45/06 ,  A61K9/00 ,  A61K47/26 ,  A61K47/44

CPC classification number: A61K31/121 ,  A61K9/0048 ,  A61K9/0053 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K47/44

Abstract: A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which (a) is a mixture of (5E,9E,13E)-geranylgeranylacetone and (5Z,9E,13E)-geranylgeranylacetone, the (5E,9E,13E)-geranylgeranylacetone content of the mixture being 80% by weight or more, (b) consists of (5E,9E,13E)-geranylgeranylacetone, or (c) consists of (5Z,9E,13E)-geranylgeranylacetone directly suppresses the death of a retinal cell, thereby fundamentally preventing, ameliorating or treating the retinal disease.

公开(公告)号：US09427473B2

公开(公告)日：2016-08-30

申请号：US14384810

申请日：2013-11-29

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Ryo Komurasaki ,  Yoko Mizutare ,  Atsuko Nakata

IPC: A61K31/07 ,  A61K31/23 ,  A61K47/44 ,  A61K47/10 ,  A61K47/14 ,  A61K9/00 ,  A01N25/22 ,  A01N37/36

CPC classification number: A61K47/44 ,  A01N25/22 ,  A01N37/36 ,  A61K9/0048 ,  A61K31/07 ,  A61K31/23 ,  A61K47/10 ,  A61K47/14 ,  A61K47/34

Abstract: The present invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil, (B) polyethylene glycol monostearate, and (C) at least one member selected from the group consisting of sesame oil, castor oil, vitamin A, and chlorobutanol.

Abstract translation: 本发明涉及包含（A）聚氧乙烯蓖麻油，（B）聚乙二醇单硬脂酸酯和（C）至少一种选自由芝麻油，蓖麻油，维生素A和氯丁醇组成的组的组合物的水性眼用组合物。

公开(公告)号：US09422246B2

公开(公告)日：2016-08-23

申请号：US14389139

申请日：2013-03-27

Applicant: ROHTO Pharmaceutical Co., Ltd.

Inventor： Takashi Shimizu

IPC: C07D233/96 ,  A61Q17/04 ,  A61K8/49 ,  A61Q19/00

CPC classification number: C07D233/96 ,  A61K8/49 ,  A61K8/494 ,  A61K8/4946 ,  A61Q17/04 ,  A61Q19/00

Abstract: A novel compound which has excellent ultraviolet-absorbing function (especially UVA absorbing function) and excellent hydrophilicity. A benzylidene azolidine derivative represented by structural formula (I) or a salt thereof. In structural formula (I), n represents an integer of 1-5; A1 represents O, S or N-A4; and each of A2, A3 and A4 independently represents a hydrogen atom, an alkyl group which may be substituted by a hydroxyl group and has 1-8 carbon atoms, or the like (provided that at least one of A2, A3 and A4 contains one or more hydroxyl groups). In this connection, when n is an integer of 2-5, the plurality of A3O— moieties may be the same as or different.

Abstract translation: 具有优异的紫外线吸收功能（特别是UVA吸收功能）和优异亲水性的新型化合物。 由结构式（I）表示的亚苄基偶氮化合物衍生物或其盐。 在结构式（I）中，n表示1-5的整数; A1代表O，S或N-A4; A2，A3和A4各自独立地表示氢原子，可以被羟基取代并具有1-8个碳原子的烷基等（条件是A2，A3和A4中的至少一个包含一个 或更多的羟基）。 在这一点上，当n为2-5的整数时，多个A3O-部分可以相同或不同。